Radius Health (NASDAQ:RDUS) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.15, Briefing.com reports. Radius Health had a negative net margin of 98.22% and a negative return on equity of 506.35%. The firm had revenue of $46.77 million during the quarter, compared to analyst estimates of $45.69 million. During the same period last year, the firm posted ($1.09) earnings per share. Radius Health’s revenue for the quarter was up 69.2% compared to the same quarter last year.
Shares of NASDAQ:RDUS traded up $0.86 on Friday, hitting $24.85. 639,918 shares of the company’s stock were exchanged, compared to its average volume of 564,637. Radius Health has a 12 month low of $12.81 and a 12 month high of $29.97. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -5.09 and a beta of 0.83. The business’s 50 day simple moving average is $26.78 and its two-hundred day simple moving average is $23.99. The company has a debt-to-equity ratio of 6.75, a current ratio of 4.38 and a quick ratio of 4.28.
A number of research analysts recently weighed in on RDUS shares. Morgan Stanley started coverage on shares of Radius Health in a report on Thursday, September 5th. They issued a “buy” rating and a $43.00 target price for the company. Citigroup raised shares of Radius Health from a “neutral” rating to a “buy” rating and raised their target price for the company from $24.00 to $40.00 in a report on Thursday, August 29th. Leerink Swann cut their target price on shares of Radius Health from $49.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday. ValuEngine lowered shares of Radius Health from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 2nd. Finally, HC Wainwright reaffirmed a “hold” rating and set a $27.00 price objective on shares of Radius Health in a research note on Thursday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $33.43.
Radius Health Company Profile
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Featured Story: Percentage Decliners
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.